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Reply from the Authors The antiproteinuric effect of
We thank Dr. Goto for drawing attention to the blood
pressure data in our study on dual blockade of the renin- high-dose ramipril: Still an
angiotensin system (RAS). The blood pressure data are
indeed of interest, although our study was designed spe- open question
cifically to test for the antiproteinuric effects of dual
blockade versus monotherapy [1]. Dr. Goto correctly
To the Editor: The effect of maximum tolerated dosesnotes that, because of the timing of administration, one
of ramipril on proteinuria has been recently evaluated inhas to be cautious in interpreting the comparisons be-
19 adult patients with chronic non-diabetic glomerulo-tween monotherapy and combined therapy, and that fur-
nephrities, nephrotic proteinuria (5.5 g/day, range 3.5 tother studies are necessary to address this issue. However,
18.4), or normal or impaired filtration (serum creatininewe want to emphasize that we used the dosing regimen
1.55 mg/dL, range 0.6 to 3.65), and undergoing treatmentmost often applied in clinical practice.
with angiotensin-converting enzyme (ACE) inhibitors forDr Goto further questions whether the finding in renal
at least 6 months [1] (Fig. 1, point a). Patients entered apatients can or should be extrapolated to essential hyper-
2-month washout period from antihypertensive medica-tension. As a general rule, extrapolation of data from one
tions with the exception of diuretics and occasional admin-patient category to another is hazardous, and we fully agree
istration of nifedipine (Fig. 1, point b). In a 2-month up-that the data should be confirmed for such other set-
titration period (ramipril 2.5 to 20 mg/day), the maximumtings. In addition, the actual aim with treatment of hyper-
tolerated dose was identified (Fig. 1, point c), continuedtension is, rather than lowering the blood pressure, to
for 2 additional months (ramipril alone or with indometha-reduce end-organ damage. Recent data, such as from the
cin, in crossover (Fig. 1, points d and e, respectively), andLosartan Intervention for End Point (LIFE) study [2],
then withdrawn in the recovery (Fig. 1, point f).suggest that RAS blockade may provide end-organ pro-
A significant reduction of both proteinuria (28%; fromtection beyond blood pressure control, but no intermedi-
5.6 to 4.0 g/day, remission rate not reported) and non-ate parameter is currently known to reflect this in essen-
selective glomerular membrane shunt parameter (o)tial hypertension. In renal disease, however, proteinuria
(greater than 50%) was observed by the end of the up-titra-is a well-established parameter indicating the efficacy
tion period and during the crossover phase and was at-of protection against end-organ damage [3] and in our
tributed to the treatment with high doses of ramiprilexperience higher doses than necessary for blood pres-
[1]. During the study, however, blood pressure changedsure control are often needed for maximal reduction of
accordingly with a notable apparent threshold value ofproteinuria (abstract, Laverman et al, J Am Soc Nephrol
130/80 mm Hg (Fig. 1), below which there was a reduc-13: P265A, 2002). Therefore, if such a parameter was
tion in both proteinuria and o. Of note, before the studyidentified also in hypertension, an approach analogous
(Fig. 1, point a), patients were already on ACE inhibi-to ours of titration for proteinuria in renal patients [1]
tors, and thereafter, a greater proteinuria reduction wasmight prove valuable to optimize end-organ protection
observed in patients receiving ramipril plus loop diuret-with RAS blockade.
ics versus thiazides, further indicating a blood pressure,
not ACE inhibitor effect, causing proteinuria reduction.Gozewijn D. Laverman, Gerjan J. Navis,
Robert H. Hennning, Paul E. de Jong, Furthermore, in patients with non–insulin-dependent di-
and Dick De Zeeuw abetes mellitus, whose blood pressure was maintained
Groningen, The Netherlands at 148/88 mm Hg or 150/86 mm Hg with perindopril or
nitrendipine, respectively, neither proteinuria nor mem-Correspondence to Gozewijn D. Laverman, M.D., Deptartment of
Internal Medicine, Division of Nephrology, University Hospital Gron- brane pore size distribution changed after 10 weeks [2].
ingen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands. In addition, the validity of o parameter is called intoE-mail: gd_laverman@hotmail.com
question, as the calculation was based on measured clear-
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